Mosquirix: WHO Approves First Malaria Vaccine in Africa
On October 6, a new malaria drug, RTS, S / ASO1 (RTS.S), named Mosquirix, got its first approval from WHO. The drug also reduces severe life-threatening diseases and malaria. A vaccine against malaria should only be tested on children in Africa so far.
Plasmodium falciparum, the most prevalent malaria parasite in Africa. It remains attacked by this vaccine, which means the world’s most deadly malaria parasite. Four out of ten cases of malaria did prevent in four years among children who survived given four doses of the Malaria vaccine in a clinical trial.
The Malaria disease solution received a positive response from the European Medicines Agency(EMA). Really, it was great news. However, this is the first malaria vaccine to complete the clinical development process and receive positive scientific opinions.
As a result of this initiative, the Ministry of Health has introduced the malaria vaccine in three countries through a pediatric vaccination program. Within three countries, Ghana, Kenya, and Malawi, more than 800,000 children have benefited from the vaccination program.
“FEAR OF DISEASE KILLED MORE MEN THAN DISEASE ITSELF.”
Moreover, the clinical evidence suggests that, when in combination with other recommended malaria interventions, the vaccine does strategically administered shortly before the peak season of malaria infection. This study shows that the mortality rate can greatly reduce while the effects can optimize.
Malaria is a life-threatening disease caused by parasites that infect humans after being bitten by an infected Anopheles mosquito. It is preventable and treatable.
However, in 2019, there were an estimated 229 million malaria outbreaks worldwide, with an estimated 409,000 deaths from malaria that year.
Most of the malaria cases occur among children under five years of age. Approximately 274 thousand people died of malaria worldwide in 2019.
According to the World Health Organization, the estimated number of malaria cases in India in 2019 is 5.6 million, compared to about 20 million in 2020.